OP007: A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitisECCO'17 Barcelona 2017
1
OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn’s Disease: 52-week results of a phase III randomised controlled trialECCO'17 Barcelona 2017
1
OP010: Long term efficacy and safety of Ustekinumab for Crohn’s Disease: Results from IM-UNITI long-term extension through 2 yearsECCO'17 Barcelona 2017
1
OP011:Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY studyECCO'17 Barcelona 2017
1
OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with Ulcerative Colitis undergoing (procto)colectomy with ileal pouch- anal anastomosisECCO'17 Barcelona 2017
1
OP013: Disease management and outcomes of patients with Crohn’s Disease at high risk of recurrence. Results from PRACTICROHN studyECCO'17 Barcelona 2017
1
OP014: Histological remission is predictive of improved clinical outcomes in patients with Ulcerative Colitis: Results from the TOUCHSTONE OLEECCO'17 Barcelona 2017
1
OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn’s Disease: THE LIR!C TRIALECCO'17 Barcelona 2017
1
OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoachECCO'17 Barcelona 2017
1
OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn’s Disease treated with mongersen (GED- 0301)ECCO'17 Barcelona 2017
1
OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn DiseaseECCO'17 Barcelona 2017
1
OP021: Hyperbaric oxygen therapy is safe and effective for hospitalised Ulcerative Colitis patients suffering from moderate- severe flares: A multi-center, randomised, double-blind, sham- controlled trialECCO'17 Barcelona 2017
1
OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character studyECCO'17 Barcelona 2017
1
OP023: Maintenance of clinical effect in patients with moderate- to-severe Crohn’s Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY studyECCO'17 Barcelona 2017
1
OP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014ECCO'17 Barcelona 2017
1